Screener
G&A at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $44,265 | $32,415 | $90,405 | $63,329 |
| General and administrative | 13,119 | 9,278 | 24,287 | 18,416 |
| Total operating expenses | 57,384 | 41,693 | 114,692 | 81,745 |
| Loss from operations | (57,384) | (41,693) | (114,692) | (81,745) |
| Other income, net: | ||||
| Interest income | 3,221 | 2,966 | 5,285 | 5,266 |
| Interest expense | — | (60) | — | (128) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s G&A?
- Solid Biosciences Inc. (SLDB) reported G&A of $13.12M in Q2 2026.
- How has Solid Biosciences Inc.'s G&A changed year-over-year?
- Solid Biosciences Inc.'s G&A increased by 41.4% year-over-year, from $9.28M to $13.12M.
- What is the long-term trend for Solid Biosciences Inc.'s G&A?
- Over 4 years (2021 to 2025), Solid Biosciences Inc.'s G&A has grown at a 9.4% compound annual growth rate (CAGR), from $27.14M to $38.88M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Solid Biosciences Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude